CPT code 81404 – Tier 4 molecular pathology procedure

Key Takeaways

CPT code 81404 covers Tier 4 molecular pathology procedures, including sequence analysis for analytes at moderate-to-high complexity, distinct from adjacent Tier 3 (81403) and Tier 5 (81405) codes

CMS LCD L35000 and Billing and Coding Article 56199 govern Medicare coverage for 81404; non-covered indications require an Advance Beneficiary Notice before testing

Wrong-tier assignment and mismatched ICD-10/analyte pairs are the two leading automated denial triggers; selecting 81403 instead of 81404 is a common audit flag

Pabau’s claims management software streamlines CPT 81404 claim submission, tracks prior authorization status, and surfaces ERA denial codes to reduce rework

CPT code 81404: official descriptor and tier classification

CPT code 81404 is a Tier 4 molecular pathology procedure code in the AMA’s 81400-81408 tier series, assigned to gene sequence analyses that require moderate-to-high analytical complexity. The official AMA descriptor reads: Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons).

The tier system is based on analytical complexity, not clinical significance. A gene analyte’s complexity level determines which 814xx code applies. Coders cannot select a tier based on the clinical importance of the result or the patient’s diagnosis alone.

The AMA CPT Editorial Panel updates the analyte lists under each tier annually. Always verify against the current AMA CPT code set before billing a new gene test.

Which genes and procedures does CPT code 81404 cover?

CPT code 81404 covers sequence analysis and mutation detection for gene analytes whose procedural complexity meets the Tier 4 definition. The analytes explicitly named in the 81404 descriptor include, but may not be limited to, the following. Always verify against the current AMA CPT manual, as the list is updated annually.

When the ordered gene analyte is not named in the 81404 descriptor, do not force it into this tier. Use CPT code 81479 (unlisted molecular pathology procedure) instead, and submit with a cover letter explaining the analyte, methodology, and tier justification.

CPT 81404 vs 81403 vs 81405: choosing the right tier

Selecting the wrong tier is one of the most common audit triggers in molecular pathology billing, and the 81403/81404 boundary is where most errors occur. The differentiator is procedural complexity, specifically the number of exons analyzed and the amplicon count in multiplex PCR reactions.

Use this decision sequence before assigning a tier to any molecular pathology order:

1. Is the analyte named in a specific 814xx descriptor? If yes, use that code. If no, use 81479.
2. How many exons are being analyzed by sequence analysis? One exon maps to 81404. Two to five exons maps to 81405. Six to ten exons maps to 81406.
3. If using multiplex PCR, how many amplicons? Two to ten amplicons in a single reaction maps to 81403. More than ten amplicons in two or more independent reactions maps to 81404.
4. Is the procedure targeted mutation scanning rather than full sequence analysis? Scanning of two to five exons maps to 81404. Scanning of a single exon maps to 81403.

Coders who skip step one and assign a tier based on the gene’s clinical relevance rather than its procedural complexity create the mismatch that automated NCCI edits catch. Understanding the molecular pathology billing process from order to payment prevents these downstream errors.

When to use CPT 81479 instead of 81404

Use CPT 81479 when the specific gene analyte is not listed in the 81404 (or any other 814xx) descriptor. Payers treat 81479 as an unlisted code requiring manual pricing, so submission requires a cover letter with the analyte name, methodology, peer-reviewed literature supporting medical necessity, and a suggested fee based on a comparable named code. Most payers will not auto-adjudicate 81479; expect processing delays of four to twelve weeks.

Medicare coverage and CMS policy for CPT code 81404

Medicare coverage for CPT code 81404 is governed by CMS LCD L35000 (Molecular Pathology Procedures) and Billing and Coding Article ID 56199. LCD L35000 defines which genetic indications are covered, which are non-covered, and under what clinical circumstances an Advance Beneficiary Notice (ABN) is required before testing.

Coverage under LCD L35000 generally requires that the test result will directly influence patient management. Screening genetic tests in asymptomatic patients without a family history trigger or a documented clinical indication are typically non-covered. Refer to the live CMS Physician Fee Schedule lookup for current payment rates, as LCD text is subject to revision and cannot be quoted as static.

• Covered: Germline mutation testing for an analyte listed in 81404 when the patient has a documented clinical indication (active disease, family history meeting payer criteria, or prior test suggesting hereditary risk)
• Non-covered: Population screening without clinical indication; off-label investigational testing; tests where the result will not change management
• ABN required: When coverage is uncertain because the indication may not meet LCD L35000 criteria; issuing an ABN protects the lab and shifts financial responsibility to the patient if Medicare denies

Medicare reimbursement rate for CPT code 81404

CPT code 81404 is priced under the Clinical Laboratory Fee Schedule (CLFS), not the Medicare Physician Fee Schedule. CLFS rates are national (no geographic adjustment applies to lab codes) and update annually on January 1. For the current payment amount, look up code 81404 directly in the CMS CLFS data file, which CMS publishes each November for the following calendar year.

Payment is made to the performing laboratory. If the ordering physician separately interprets the result, modifier 26 (professional component) may apply to certain codes, but most molecular pathology services under 81404 are global, meaning one payment covers both technical and professional components. Verify modifier applicability with your MAC before billing. After adjudication, reading electronic remittance advice correctly tells you whether the claim paid at the expected CLFS rate or was adjusted.

Prior authorization requirements for CPT code 81404

Prior authorization for CPT code 81404 is not universally required by Medicare fee-for-service, but it is routinely required by Medicare Advantage plans and most commercial insurers. Failure to obtain prior authorization when it is required is the leading single cause of denial for this code.

Strong medical billing compliance practices require verifying authorization requirements for every payer before the specimen is collected, not after results are reported. Retroactive authorization requests are accepted by fewer than half of commercial plans and are almost never granted by Medicare Advantage plans once testing is complete.

ICD-10 codes that support CPT code 81404

Payers cross-reference the ICD-10 diagnosis code on the claim against the gene analyte ordered. A mismatched pair triggers automated denial before a human reviewer ever sees the claim. The diagnosis must reflect the clinical condition that makes the specific analyte medically necessary, not a general “genetic testing” or “screening” code where the LCD does not support it.

Use the most specific ICD-10 code available. A Z13.xx screening code paired with a disease-specific gene analyte (e.g. PYGM for McArdle disease) often fails automated medical necessity checks because the diagnosis code implies surveillance rather than diagnostic work-up. Confirm the exact supported pairings with a CPT-to-ICD-10 crosswalk tool or your MAC’s LCD companion article before submission.

Documentation requirements for billing CPT code 81404

Every CPT code 81404 claim must be supported by documentation that exists in the medical record before the claim is submitted. Retroactive documentation created after a denial is rarely accepted during appeal and may create compliance exposure.

The following elements must be present. Pabau’s claims management software can attach documentation flags to orders so labs verify completeness before the specimen ships.

• Ordering provider note: A clinical note from the ordering provider that establishes the specific clinical indication, documents relevant personal and family history, and states the medical necessity for the named gene analyte
• Specific analyte ordered: The requisition must name the exact gene analyte, not just “genetic testing” or “molecular panel”; mismatched analyte references between the requisition and the laboratory report are a common denial trigger
• Specimen type and collection date: Date of collection, specimen type (blood, buccal swab, tissue), and chain of custody documentation
• Laboratory report: The final laboratory report naming the specific gene tested, methodology used, and result interpretation; this report is the primary document attached during appeals
• Place of service code: Molecular pathology services are typically billed with POS 81 (independent laboratory); using POS 11 (office) when the performing entity is a reference lab is a billing error
• ABN (where required): Signed and dated ABN with the patient’s acknowledgment, required before service is rendered in any non-covered or potentially non-covered indication

Achieving a clean claim submission on the first pass requires all six elements to be verified before the claim file is generated. Labs using manual workflows frequently miss the ABN step and the specific analyte documentation, both of which are almost impossible to correct post-denial without creating a compliance gap.

Reduce CPT 81404 claim denials with Pabau

Pabau tracks prior authorization status, attaches documentation checklists to molecular pathology orders, and surfaces ERA denial codes so your team can act before the appeal window closes. See how it works for lab billing workflows.

Book a demo

Common denial reasons for CPT code 81404 and how to prevent them

Most CPT code 81404 denials are preventable. The patterns below account for the majority of rejections in lab billing workflows; each maps to a corrective action and indicates whether an appeal is viable. Understanding denial management workflows specific to molecular pathology codes shortens the revenue cycle significantly.

Review common denial codes in medical billing to map ERA adjustment reason codes (CARCs) back to the root causes above. CARC 57 (“Prior authorization not obtained”) and CARC 4 (“The service/supply/procedure is inconsistent with the diagnosis”) are the two you will see most often on rejected 81404 claims. Pabau’s integration with the Claim.MD clearinghouse integration surfaces these denial codes in the claims dashboard so revenue cycle staff can act within the appeal window, not weeks after it closes.

How to appeal a denied CPT 81404 claim

A denied CPT code 81404 claim is not automatically final. Most payers and Medicare provide a formal appeal process with defined timelines.

1. Identify the denial reason from the ERA. The CARC code tells you whether the denial is clinical (wrong indication) or administrative (missing PA, wrong POS). Administrative denials are usually resolved with a corrected claim, not an appeal.
2. For Medicare redetermination: File within 120 days of the denial notice. Submit the corrected claim or redetermination request to your MAC with the ordering provider’s clinical note, the laboratory report, and a letter of medical necessity if the denial was for non-covered indication.
3. For commercial payer appeals: Most plans require appeal submission within 90 to 180 days of the denial date. Include all documentation listed in the documentation requirements section, plus a copy of the EOB showing the denial.
4. Escalation for Medicare: If redetermination is upheld, escalate to Qualified Independent Contractor (QIC) review, then Administrative Law Judge (ALJ) hearing. ALJ hearings are available only when the amount in controversy exceeds the annual threshold (currently $180 for 2026).
5. Track appeal deadlines rigorously. A missed appeal window is an unrecoverable write-off for most labs. Assign denial ownership by code and payer so no 81404 denial ages past 60 days without a response filed.

Conclusion

CPT code 81404 denials almost always trace back to one of three gaps: the wrong tier was selected, the ICD-10 code did not match the analyte, or prior authorization was not secured before collection. All three are fixable before the claim is submitted.

Pabau’s claims management software tracks prior authorization status against open orders, flags documentation gaps before submission, and uses the Claim.MD clearinghouse connection to surface ERA denial codes the same day they post. Fewer rework cycles mean faster payment and a cleaner revenue cycle for molecular pathology labs.

To see how the workflow fits your lab’s billing setup, book a demo.

Continue your research

Need to understand how clearinghouse submissions work? Medical claims clearinghouse overview explains how electronic claims move from lab to payer and where errors are caught.

Want to reduce claim rework across your billing team? Superbill documentation guide covers how complete superbills prevent the most common lab billing errors before submission.

Exploring credentialing requirements for ordering providers? Provider credentialing with insurance companies outlines the enrollment steps that affect claim acceptance for reference labs.

Frequently Asked Questions